COLL News and Press, Collegium Pharmaceutical Inc. From 01/06/21

Collegium Pharmaceutical (COLL) provides its FY2021 guidance as follows:Xtampza ER revenues expected to be in the range of $155-$165MNucynta franchise revenues in the range of $175-$185M.Adj. EBITDA (excluding stock-based compensation) is expected in the range of $160-$170M.Tot...

– Xtampza ® ER Revenues Expected in the Range of $155.0 million to $165.0 million – – Nucynta ® Franchise Revenues Expected in the Range of $175.0 million to $185.0 million – – Adjusted EBITDA Expected ...

Collegium Pharmaceutical recently reported their Q3 earnings with a beat on EPS and revenue. Despite some serious COVID-19 headwinds, Collegium was able to record another quarter of growth and increase their cash on hand while paying down debt. I believe the company has laid the g...

Collegium Pharmaceutical, Inc. (COLL) Q3 2020 Earnings Conference Call November 06, 2020 4:30 PM ET Company Participants Alex Dasalla - Head of Investor Relations Joe Ciaffoni - Chief Executive Officer Paul Brannelly - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Conference...

Image source: The Motley Fool. Collegium Pharmaceutical Inc (NASDAQ: COLL) Q3 2020 Earnings Call Nov 6, 2020 , 4:30 p.m. ET Operator Continue reading For further details see: Collegium Pharmaceutical Inc (COLL) Q3 2020 Earnings Call Trans...

– Strengthened Formulary Access for Xtampza ® ER, Including Exclusive National Medicare Part D Win – – Generated $34.2 Million in Cash Flow from Operations – – Adjusted EBITDA of $41.8 Million – ...

[[AAXN]], [[ACLS]], [[ADT]], [[AGO]], [[AIG]], [[AINV]], [[ALRM]], [[ALTR]], [[AMCR]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[ATGE]], [[ATRC]], [[AVLR]], [[AYX]], [[AZPN]], [[BFAM]], [[BGS]], [[BHF]], [[BIGC]], [[BILL]], [[BKNG]], [[BLDP]], [[BMRN]], [[BNFT]], [[CABO]], [[CARG]], [[CDAY]], [...

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to announce Q3 earnings results on Wednesday, November 4th, after market close.The consensus EPS Estimate is $0.90 (+600.0% Y/Y) and the consensus Revenue Estimate is $77.39M (+6.1% Y/Y).Over the last 1 year, COLL has beaten EPS estimates 50...

STOUGHTON, Mass., Oct. 26, 2020 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced a publication titled, “Postmarketing Analysis of Misuse, Abu...

Collegium Pharmaceuticals (NASDAQ: COLL) and Athenex (NASDAQ: ATNX) may not be the most popular stocks on the market in terms of media coverage, but both might just make you rich with a well-timed investment. Unlike many of their compatriots in the world of small market cap ...